SRTS Stock Analysis: Buy, Sell, or Hold?
SRTS - Sensus Healthcare, Inc
$5.13
-0.05 (-0.97%)
▼
5d:
+6.21%
30d:
+38.65%
90d:
+59.81%
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 04, 2026
1d
Get Alerted When SRTS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: SRTS shows positive signals but monitor for confirmation. Market pricing in 6.7% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: SRTS shows positive signals but monitor for confirmation. Market pricing in 6.7% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: SRTS is currently trading at $5.13, which is considered slightly high relative to its 30-day fair value range of $4.18 to $5.17. From a valuation perspective, the stock is trading at a premium (Forward PE: 513.0) compared to its historical average (422.5). At these levels, the market is pricing in 6.7% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SRTS is in a strong uptrend. Immediate support is located at $4.64, while resistance sits at $5.36.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.33 (+42.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SRTS is in a strong uptrend. Immediate support is located at $4.64, while resistance sits at $5.36.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.33 (+42.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$4.18 -
$5.17
Company Quality Score
55/100
(HOLD)
Options IV Signal
47th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
66.2%
All Signals
- NEUTRAL: Options fairly priced (IV 47th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 42.9% below Wall St target ($7.33)
- NEUTRAL: PE elevated vs history but 6.7% growth expectation is conservative given 433% recent growth
Fair Price Analysis
30-Day Fair Range
$4.18 -
$5.17
Current vs Fair Value
SLIGHTLY HIGH
Expected Move (7 Days)
±$0.91
(17.8%)
Support & Resistance Levels
Support Level
$4.64
Resistance Level
$5.36
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
513.00
Wall Street Target
$7.33
(+42.9%)
Revenue Growth (YoY)
155.7%
Earnings Growth (YoY)
433.3%
Profit Margin
-8.4%
Valuation Premium vs History
+6.7% premium
PE vs Historical
513.0 vs 422.5
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+6.7%
(market-implied from PE analysis)
1-Year Target
$5.47
(+7%)
2-Year Target
$5.84
(+14%)
3-Year Target
$6.23
(+22%)
3-Yr Target (if PE normalizes)
(PE: 513→423)
PE COMPRESSION
$5.13
(0%)
Earnings growth offset by PE compression
Last updated: February 02, 2026 4:09 AM ET
Data refreshes hourly during market hours. Next update: 5:09 AM
Data refreshes hourly during market hours. Next update: 5:09 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SRTS showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Michael Sardano
BUY
1000 shares
2025-08-13
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$124 | 59 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$85 | 65 BUY |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$134 | 63 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$111 | 63 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
23 analysts |
$370 | 54 HOLD |
